July 2024 Issue

Watch for Resmetirom to Treat NASH

Resmetirom (Rezdiffra) will be the first med approved for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis in adults...

GO TO FULL ISSUE

What is Prescriber Insights: MD?

Prescriber Insights: MD is the fastest, most trustworthy way for physicians to find out how drug therapy changes should fit into your practice. It's unbiased, evidence-based, and 100% free from financial support of the pharma industry. Learn more >


NetCE. A TRC Healthcare Brand. All Access: PA. Easily Meet State Mandates. Get unlimited access to 1,000+ hours of CME that meets state mandates exclusively for physicians. Learn More

Unlock More

Prescriber Insights: MD is one of many medication advisory and CE solutions from TRC Healthcare for physicians. Learn more about:


Group Purchases & Pricing

Prescriber Insights: MD is eligible for bulk discounts. Easy for admins to manage access, easy for staff to track CME requirements. Bundle with more evidence-based tools for big savings. Request information